Crinetics Pharma's Investigational Candidate Shows Promise In Rare Type Of Hormonal Disorder
Portfolio Pulse from Vandana Singh
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) announced that its Phase 3 PATHFNDR-1 study evaluating paltusotine met the primary and secondary endpoints in acromegaly patients. The company plans to submit a new drug application to the FDA in 2024. The company's shares are up 67.40% at $26.74.
September 11, 2023 | 2:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Crinetics Pharmaceuticals' successful Phase 3 study and plans for FDA application in 2024 have led to a significant increase in its stock price.
The successful results of the Phase 3 study and the company's plans to submit a new drug application to the FDA in 2024 have positively impacted investor sentiment, leading to a significant increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100